Intensive Cancer Screening After Cryptogenic Stroke
ConditionOccult Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorOttawa Hospital Research Institute
About this trial
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Eligibility criteria
Qualifiers
adults ≥18 years
presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)
patient or delegate willing and able to provide informed consent.
Disqualifiers
contraindications to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes)
active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)
Trial design
Treatments tested in this trial
- FDG PET/CT
- Usual Care
Treatment groups
45 Participants
are divided into 2 treatment groupsSponsors and collaborators
Ottawa Hospital Research Institute
Lead sponsor
Brain Canada
Collaborator
Heart and Stroke Foundation of Canada
Collaborator
Canadian Stroke Consortium (CSC)
Collaborator
Source ClinicalTrials.gov